Antonella Chadha Santuccione, MD, Co-founder and CEO of the Women’s Brain Project and Chief Medical Officer at Altoida Inc., spotlights sex- and gender-based research as the gateway to precision medicine. Substantial sex and gender differences are seen in Alzheimer’s disease, from prevalence rates and diagnostic pathways to progression trajectories, treatment responses, and health outcomes. For this reason, it is crucial to prioritize sex and gender factors at all stages of research and implementation. The Women’s Brain Project (WBP) non-profit organization has launched a call to action, to prioritize brain and mental health through a sex and gender lens, through policymaking and economic prioritization, robust research, education, and meaningful involvement of patients and caregivers in decision-making. The WBP will work with scientists, healthcare professionals, policymakers, regulatory, the pharmaceutical industry, and patients and carers to transform the clinical trial landscape. Dr Chadha Santuccione emphasizes the need for a more inclusive agenda at all stages of research, to achieve precision medicine and improve outcomes. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
